Sorry OT >> Didn't realize the Eligix market was that large. <<
Not trying to defend Punk, Ziegel on the $3.9B estimate. However, there are over 60,000 procedures performed worldwide now, and this would make the average cost of each procedure between $60-$65K, which seems reasonable.
Of course, how much of that could go to BTRN process or Eligix equipment is not discussed! Their treatment process using 507 is, of course, not approved, so no revenue estimates for BTRN should be made for that procedure.
BTRN has said that the market potential for B Cell HDM and T Cell HDM equipment is appx. $150MM each for a total of $300MM. IF the AlloMune Process gains approval at some future date, then BTRN would stand to gain very substantial revenues, possibly approaching $1B.
Rick, you have said that there is still a long road to hoe here. We will sincerely wish them the best of luck in achieving success. If they were successful, the number of patients would probably expand due to the higher potential success of the procedure. BTRN continues to be the most fascinating company that I am watching. I hope that this clarification adds a little light. Mark |
